DexCom, Inc.

Valuation Analysis

About the Company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc. Stock at a Glance

DexCom, Inc. (DXCM) is currently trading at $75.37 with a market capitalization of $29.1B. The trailing P/E ratio stands at 32.35x, with a forward P/E of 24.46x. The 52-week range spans from $54.11 to $89.98; the current price is 16.2% below the yearly high. Year-over-year revenue growth stands at +15.0%. The net profit margin stands at 19.31%.

💰 Dividend

DexCom, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

24 analysts rate DexCom, Inc. (DXCM) on consensus: Strong Buy. The average price target is $84.67, implying +12.33% from the current price. Analyst price targets range from $65.00 to $112.00.

DexCom, Inc.: The Investment Case in Detail

DexCom, Inc. (DXCM) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 15% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 92.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 61.5%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.41 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 24.46x is meaningfully below the trailing 32.35x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (5.19%).

Trading Data

Related Stocks in the Same Sector

Where can I buy DexCom, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.